An overview of mesenchymal stem cells and their potential therapeutic benefits in cancer therapy (Review)
- Authors:
- Shern Kwok Lim
- Boon Yin Khoo
-
Affiliations: Institute for Research in Molecular Medicine, Universiti Sains Malaysia, 11800 Penang, Malaysia - Published online on: September 14, 2021 https://doi.org/10.3892/ol.2021.13046
- Article Number: 785
-
Copyright: © Lim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Watt FM and Driskell RR: The therapeutic potential of stem cells. Philos Trans R Soc B Biol Sci. 365:155–163. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Alvarez CV, Garcia-Lavandeira M, Garcia-Rendueles MER, Diaz-Rodriguez E, Garcia-Rendueles AR, Perez-Romero S, Vila TV, Rodrigues JS, Lear PV and Bravo SB: Defining stem cell types: Understanding the therapeutic potential of ESCs, ASCs, and iPS cells. J Mol Endocrinol. 49:R89–R111. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zakrzewski W, Dobrzyński M, Szymonowicz M and Rybak Z: Stem cells: Past, present, and future. Stem Cell Res Ther. 10:682019. View Article : Google Scholar : PubMed/NCBI | |
|
Singh VK, Saini A, Kalsan M, Kumar N and Chandra R: Describing the stem cell potency: The various methods of functional assessment and in silico diagnostics. Front Cell Dev Biol. 4:1342016. View Article : Google Scholar : PubMed/NCBI | |
|
Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM and Caplan AI: Mesenchymal stem cell perspective: Cell biology to clinical progress. NPJ Regen Med. 4:222019. View Article : Google Scholar : PubMed/NCBI | |
|
Martin GR: Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA. 78:7634–7638. 1981. View Article : Google Scholar : PubMed/NCBI | |
|
Friedenstein AJ, Chailakhjan RK and Lalykina KS: The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 3:393–403. 1970.PubMed/NCBI | |
|
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS and Jones JM: Embryonic stem cell lines derived from human blastocysts. Science. 282:1145–1147. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Haynesworth SE, Goshima J, Goldberg VM and Caplan AI: Characterization of cells with osteogenic potential from human marrow. Bone. 13:81–88. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
McLeod C and Baylis F: Feminists on the inalienability of human embryos. Hypatia. 21:1–14. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Caulfield T and Ogbogu U: Stem cell research, scientific freedom and the commodification concern. EMBO Rep. 13:12–16. 2012. View Article : Google Scholar | |
|
Marway H, Johnson SL and Widdows H: Commodification of human tissue. Handbook of Global Bioethics. ten Have H.A.M.J and Gordijn B: Springer Netherlands; Dordrecht, Netherlands: pp. 581–598. 2014, View Article : Google Scholar | |
|
Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH and Bang OY; STARTING collaborators, : A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 28:1099–1106. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bhasin A, Srivastava MVP, Kumaran SS, Mohanty S, Bhatia R, Bose S, Gaikwad S, Garg A and Airan B: Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra. 1:93–104. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R, Waxman SG and Kocsis JD: Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 134((Pt 6)): 1790–1807. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, Du MQ, Luan SL, Altmann DR, Thompson AJ, et al: Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol. 11:150–156. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M and Tashkin DP: A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest. 143:1590–1598. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Götherström C, Westgren M, Shaw SWS, Aström E, Biswas A, Byers PH, Mattar CNZ, Graham GE, Taslimi J, Ewald U, et al: Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: A two-center experience. Stem Cells Transl Med. 3:255–264. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, et al: Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA. 311:62–73. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Karantalis V, DiFede DL, Gerstenblith G, Pham S, Symes J, Zambrano JP, Fishman J, Pattany P, McNiece I, Conte J, et al: Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The prospective randomized study of mesenchymal stem cell therapy in patients undergoing cardiac surgery (PROMETHEUS) trial. Circ Res. 114:1302–1310. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rushkevich YN, Kosmacheva SM, Zabrodets GV, Ignatenko SI, Goncharova NV, Severin IN, Likhachev SA and Potapnev MP: The use of autologous mesenchymal stem cells for cell therapy of patients with amyotrophic lateral sclerosis in Belarus. Bull Exp Biol Med. 159:576–581. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Thakkar UG, Trivedi HL, Vanikar AV and Dave SD: Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy. 17:940–947. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vega A, Martín-Ferrero MA, Del Canto F, Alberca M, García V, Munar A, Orozco L, Soler R, Fuertes JJ, Huguet M, et al: Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: A randomized controlled trial. Transplantation. 99:1681–1690. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, et al: Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS One. 13:e01958912018. View Article : Google Scholar : PubMed/NCBI | |
|
Musiał-Wysocka A, Kot M and Majka M: The pros and cons of mesenchymal stem cell-based therapies. Cell Transplant. 28:801–812. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B and Capilla-Gonzalez V: Therapeutic potential of mesenchymal stem cells for cancer therapy. Front Bioeng Biotechnol. 8:432020. View Article : Google Scholar : PubMed/NCBI | |
|
da Silva Meirelles L, Chagastelles PC and Nardi NB: Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 119((Pt 11)): 2204–2213. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Secunda R, Vennila R, Mohanashankar AM, Rajasundari M, Jeswanth S and Surendran R: Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: A comparative study. Cytotechnology. 67:793–807. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D and Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 8:315–317. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Viswanathan S, Shi Y, Galipeau J, Krampera M, Leblanc K, Martin I, Nolta J, Phinney DG and Sensebe L: Mesenchymal stem versus stromal cells: International society for cell & gene therapy (ISCT®) mesenchymal stromal cell committee position statement on nomenclature. Cytotherapy. 21:1019–1024. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Păunescu V, Deak E, Herman D, Siska IR, Tănasie G, Bunu C, Anghel S, Tatu CA, Oprea TI, Henschler R, et al: In vitro differentiation of human mesenchymal stem cells to epithelial lineage. J Cell Mol Med. 11:502–508. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, Pattany PM, Zambrano JP, Hu Q, McNiece I, et al: Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA. 106:14022–14027. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Gervois P, Struys T, Hilkens P, Bronckaers A, Ratajczak J, Politis C, Brône B, Lambrichts I and Martens W: Neurogenic maturation of human dental pulp stem cells following neurosphere generation induces morphological and electrophysiological characteristics of functional neurons. Stem Cells Dev. 24:296–311. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW and Banerjee D: Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68:4331–4339. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jotzu C, Alt E, Welte G, Li J, Hennessy BT, Devarajan E, Krishnappa S, Pinilla S, Droll L and Song YH: Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Anal Cell Pathol (Amst). 33:61–79. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Miyazaki Y, Oda T, Inagaki Y, Kushige H, Saito Y, Mori N, Takayama Y, Kumagai Y, Mitsuyama T and Kida YS: Adipose-derived mesenchymal stem cells differentiate into heterogeneous cancer-associated fibroblasts in a stroma-rich xenograft model. Sci Rep. 11:46902021. View Article : Google Scholar : PubMed/NCBI | |
|
Lee MW, Ryu S, Kim DS, Lee JW, Sung KW, Koo HH and Yoo KH: Mesenchymal stem cells in suppression or progression of hematologic malignancy: Current status and challenges. Leukemia. 33:597–611. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liang W and Chen X, Zhang S, Fang J, Chen M, Xu Y and Chen X: Mesenchymal stem cells as a double-edged sword in tumor growth: Focusing on MSC-derived cytokines. Cell Mol Biol Lett. 26:32021. View Article : Google Scholar : PubMed/NCBI | |
|
Bellagamba BC, de Abreu BRR, Grivicich I, Markarian CF, Chem E, Camassola M, Nardi NB and Dihl RR: Human mesenchymal stem cells are resistant to cytotoxic and genotoxic effects of cisplatin in vitro. Genet Mol Biol. 39:129–134. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM and Silberstein LE: Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells. 24:1030–1041. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylostalo J and Prockop DJ: The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood. 113:816–826. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Williams SA, Maecker HL, French DM, Liu J, Gregg A, Silverstein LB, Cao TC, Carano RAD and Dixit VM: USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell. 146:918–930. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuo L, Gong J, Yang R, Sheng Y, Zhou L, Kong X and Cao K: Inhibition of proliferation and differentiation and promotion of apoptosis by cyclin L2 in mouse embryonic carcinoma P19 cells. Biochem Biophys Res Commun. 390:451–457. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Puchert M and Engele J: The peculiarities of the SDF-1/CXCL12 system: In some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets. Cell Tissue Res. 355:239–253. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Janssens R, Struyf S and Proost P: The unique structural and functional features of CXCL12. Cell Mol Immunol. 15:299–311. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
De La Luz Sierra M, Yang F, Narazaki M, Salvucci O, Davis D, Yarchoan R, Zhang HH, Fales H and Tosato G: Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood. 103:2452–2459. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gomes AC, Hara T, Lim VY, Herndler-Brandstetter D, Nevius E, Sugiyama T, Tani-ichi S, Schlenner S, Richie E, Rodewald HR, et al: Hematopoietic stem cell niches produce lineage-instructive signals to control multipotent progenitor differentiation. Immunity. 45:1219–1231. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Reid JC, Tanasijevic B, Golubeva D, Boyd AL, Porras DP, Collins TJ and Bhatia M: CXCL12/CXCR4 signaling enhances human PSC-derived hematopoietic progenitor function and overcomes early in vivo transplantation failure. Stem Cell Reports. 10:1625–1641. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Binder ZA, Siu IM, Eberhart CG, Rhys CA, Bai RY, Staedtke V, Zhang H, Smoll NR, Piantadosi S, Piccirillo SG, et al: Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome. PLoS One. 8:e759452013. View Article : Google Scholar : PubMed/NCBI | |
|
Chang J, Liu F, Lee M, Wu B, Ting K, Zara JN, Soo C, Hezaimi KA, Zou W, Chen X, et al: NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci. 110:9469–9474. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kolosova IA, Angelini D, Fan C, Skinner J, Cheadle C and Johns RA: Resistin-like molecule α stimulates proliferation of mesenchymal stem cells while maintaining their multipotency. Stem Cells Dev. 22:239–247. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chosa N and Ishisaki A: Two novel mechanisms for maintenance of stemness in mesenchymal stem cells: SCRG1/BST1 axis and cell-cell adhesion through N-cadherin. Jpn Dent Sci Rev. 54:37–44. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sugiyama T, Kohara H, Noda M and Nagasawa T: Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 25:977–988. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Gharibi B, Ghuman MS and Hughes FJ: Akt- and Erk-mediated regulation of proliferation and differentiation during PDGFRβ-induced MSC self-renewal. J Cell Mol Med. 16:2789–2801. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX and Ivy SP: Targeting Notch, hedgehog, and wnt pathways in cancer stem cells: Clinical update. Nat Rev Clin Oncol. 12:445–464. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Batsali AK, Pontikoglou C, Koutroulakis D, Pavlaki KI, Damianaki A, Mavroudi I, Alpantaki K, Kouvidi E, Kontakis G and Papadaki HA: Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther. 8:1022017. View Article : Google Scholar : PubMed/NCBI | |
|
Pelullo M, Zema S, Nardozza F, Checquolo S, Screpanti I and Bellavia D: Wnt, Notch, and TGF-β pathways impinge on Hedgehog signaling complexity: An open window on cancer. Front Genet. 10:7112019. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V and Ho AD: Replicative senescence of mesenchymal stem cells: A continuous and organized process. PLoS One. 3:e22132008. View Article : Google Scholar : PubMed/NCBI | |
|
Halfon S, Abramov N, Grinblat B and Ginis I: Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev. 20:53–66. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pérez-Campo FM and Riancho JA: Epigenetic mechanisms regulating mesenchymal stem cell differentiation. Curr Genomics. 16:368–383. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Teven CM, Liu X, Hu N, Tang N, Kim SH, Huang E, Yang K, Li M, Gao JL, Liu H, et al: Epigenetic regulation of mesenchymal stem cells: A focus on osteogenic and adipogenic differentiation. Stem Cells Int. 2011:2013712011. View Article : Google Scholar : PubMed/NCBI | |
|
Srinageshwar B, Maiti P, Dunbar GL and Rossignol J: Role of epigenetics in stem cell proliferation and differentiation: Implications for treating neurodegenerative diseases. Int J Mol Sci. 17:1992016. View Article : Google Scholar : PubMed/NCBI | |
|
Escacena N, Quesada-Hernández E, Capilla-Gonzalez V, Soria B and Hmadcha A: Bottlenecks in the efficient use of advanced therapy medicinal products based on mesenchymal stromal cells. Stem Cells Int. 2015:8957142015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang D and Kilian KA: The effect of mesenchymal stem cell shape on the maintenance of multipotency. Biomaterials. 34:3962–3969. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rathbone SR, Glossop JR, Gough JE and Cartmell SH: Cyclic tensile strain upon human mesenchymal stem cells in 2D and 3D culture differentially influences CCNL2, WDR61 and BAHCC1 gene expression levels. J Mech Behav Biomed Mater. 11:82–91. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cao C, Li L, Li H, He X, Wu G and Yu X: Cyclic biaxial tensile strain promotes bone marrow-derived mesenchymal stem cells to differentiate into cardiomyocyte-like cells by miRNA-27a. Int J Biochem Cell Biol. 99:125–132. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Wang Y, Zhou N, Feng Y and Yang X: Cyclic tensile stress promotes osteogenic differentiation of adipose stem cells via ERK and p38 pathways. Stem Cell Res. 37:1014332019. View Article : Google Scholar : PubMed/NCBI | |
|
Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS and Caplan AI: Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant. 16:557–564. 1995.PubMed/NCBI | |
|
Galipeau J and Sensébé L: Mesenchymal stromal cells: Clinical challenges and therapeutic opportunities. Cell Stem Cell. 22:824–833. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S and Drela K: Challenges and controversies in human mesenchymal stem cell therapy. Stem Cells Int. 2019:96285362019. View Article : Google Scholar : PubMed/NCBI | |
|
Gálvez P, Clares B, Bermejo M, Hmadcha A and Soria B: Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use. Stem Cells Dev. 23:1074–1083. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Galvez-Martin P, Sabata R, Verges J, Zugaza JL, Ruiz A and Clares B: Mesenchymal stem cells as therapeutics agents: Quality and environmental regulatory aspects. Stem Cells Int. 2016:97834082016. View Article : Google Scholar : PubMed/NCBI | |
|
Yang YHK: Aging of mesenchymal stem cells: Implication in regenerative medicine. Regen Ther. 9:120–122. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fafián-Labora JA, Morente-López M and Arufe MC: Effect of aging on behaviour of mesenchymal stem cells. World J Stem Cells. 11:337–346. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Huang XP, Sun Z, Miyagi Y, McDonald KH, Zhang L, Weisel RD and Li RK: Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 122:2419–2429. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cho PS, Messina DJ, Hirsh EL, Chi N, Goldman SN, Lo DP, Harris IR, Popma SH, Sachs DH and Huang CA: Immunogenicity of umbilical cord tissue-derived cells. Blood. 111:430–438. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Faiella W and Atoui R: Immunotolerant properties of mesenchymal stem cells: Updated review. Stem Cells Int. 2016:18595672016. View Article : Google Scholar : PubMed/NCBI | |
|
Dhingra S, Li P, Huang XP, Guo J, Wu J, Mihic A, Li SH, Zang WF, Shen D, Weisel RD, et al: Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function. Circulation. 128((11 Suppl 1)): S69–S78. 2013.PubMed/NCBI | |
|
Gu Z, Tan W, Ji J, Feng G, Meng Y, Da Z, Guo G, Xia Y, Zhu X, Shi G and Cheng C: Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway. Aging (Albany NY). 8:1102–1114. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ankrum JA, Ong JF and Karp JM: Mesenchymal stem cells: Immune evasive, not immune privileged. Nat Biotechnol. 32:252–260. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zazzeroni L, Lanzoni G, Pasquinelli G and Ricordi C: Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes. CellR4 Repair Replace Regen Reprogram. 5:e24352017.PubMed/NCBI | |
|
Gao L, Bird AK, Meednu N, Dauenhauer K, Liesveld J, Anolik J and Looney RJ: Bone marrow-derived mesenchymal stem cells from patients with systemic lupus erythematosus have a senescence-associated secretory phenotype mediated by a mitochondrial antiviral signaling protein-interferon-β feedback loop. Arthritis Rheumatol. 69:1623–1635. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ji J, Wu Y, Meng Y, Zhang L, Feng G, Xia Y, Xue W, Zhao S, Gu Z and Shao X: JAK-STAT signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients. Acta Biochim Biophys Sin (Shanghai). 49:208–215. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Y and Feng X: Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus. Stem Cell Res Ther. 9:1492018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen DC, Lin SZ, Fan JR, Lin CH, Lee W, Lin CC, Liu YJ, Tsai CH, Chen JC, Cho DY, et al: Intracerebral implantation of autologous peripheral blood stem cells in stroke patients: A randomized phase II study. Cell Transplant. 23:1599–1612. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Taguchi A, Sakai C, Soma T, Kasahara Y, Stern DM, Kajimoto K, Ihara M, Daimon T, Yamahara K, Doi K, et al: Intravenous autologous bone marrow mononuclear cell transplantation for stroke: Phase1/2a clinical trial in a homogeneous group of stroke patients. Stem Cells Dev. 24:2207–2218. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, Yavagal DR, Uchino K, Liebeskind DS, Auchus AP, et al: Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 16:360–368. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bhatia V, Gupta V, Khurana D, Sharma RR and Khandelwal N: Randomized assessment of the safety and efficacy of intra-arterial infusion of autologous wtem cells in wubacute ischemic stroke. AJNR Am J Neuroradiol. 39:899–904. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gautam J, Alaref A, Hassan A, Kandel RS, Mishra R and Jahan N: Safety and efficacy of stem cell therapy in patients with ischemic stroke. Cureus. 12:e99172020.PubMed/NCBI | |
|
Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Mendizabal A, et al: Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J. 161:487–493. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mushtaq M, DiFede DL, Golpanian S, Khan A, Gomes SA, Mendizabal A, Heldman AW and Hare JM: Rationale and design of the percutaneous stem cell injection delivery effects on neomyogenesis in dilated cardiomyopathy (The POSEIDON-DCM Study). J Cardiovasc Transl Res. 7:769–780. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, Khan A, Mushtaq M, Lowery MH, Byrnes JJ, et al: Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 69:526–537. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula L, Weil M, Andreeff M and Marini FC: Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescence imaging. Stem Cells. 27:2614–2623. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Spaeth E, Klopp A, Dembinski J, Andreeff M and Marini F: Inflammation and tumor microenvironments: Defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 15:730–738. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kolaczkowska E and Kubes P: Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 13:159–175. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dimarino AM, Caplan AI and Bonfield TL: Mesenchymal stem cells in tissue repair. Front Immunol. 4:2012013. View Article : Google Scholar : PubMed/NCBI | |
|
Ayala-Cuellar AP, Kang JH, Jeung EB and Choi KC: Roles of mesenchymal stem cells in tissue regeneration and immunomodulation. Biomol Ther (Seoul). 27:25–33. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Julier Z, Park AJ, Briquez PS and Martino MM: Promoting tissue regeneration by modulating the immune system. Acta Biomater. 53:13–28. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Prockop DJ and Oh JY: Mesenchymal stem/stromal cells (MSCs): Role as guardians of inflammation. Mol Ther. 20:14–20. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Song J, Kang HJ, Ju HM, Park A, Park H, Hong JS, Kim CJ, Shim JY, Yu J and Choi J: Umbilical cord-derived mesenchymal stem cell extracts ameliorate atopic dermatitis in mice by reducing the T cell responses. Sci Rep. 9:66232019. View Article : Google Scholar : PubMed/NCBI | |
|
Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W, Roberts AI, Le AD, Shi S, Shao C and Shi Y: Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol. 184:2321–2328. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Zhang D, Xu L, Dong L, Zheng J, Lin Y, Huang J, Zhang Y, Tao Y, Zang X, et al: Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models. Cell Mol Immunol. 16:908–920. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Nitzsche F, Müller C, Lukomska B, Jolkkonen J, Deten A and Boltze J: Concise review: MSC adhesion cascade-insights into homing and transendothelial migration. Stem Cells. 35:1446–1460. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Caplan H, Olson SD, Kumar A, George M, Prabhakara KS, Wenzel P, Bedi S, Toledano-Furman NE, Triolo F, Kamhieh-Milz J, et al: Mesenchymal stromal cell therapeutic delivery: Translational challenges to clinical application. Front Immunol. 10:16452019. View Article : Google Scholar : PubMed/NCBI | |
|
Ullah M, Liu DD and Thakor AS: Mesenchymal stromal cell homing: Mechanisms and strategies for improvement. iScience. 15:421–438. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fiore EJ, Domínguez LM, Bayo J, García MG and Mazzolini GD: Taking advantage of the potential of mesenchymal stromal cells in liver regeneration: Cells and extracellular vesicles as therapeutic strategies. World J Gastroenterol. 24:2427–2440. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Rong P, Ma X, Nie W, Chen C, Yang C, Zhang J, Dong Q and Wang W: Paracrine effect of mesenchymal stem cell as a novel therapeutic strategy for diabetic nephropathy. Life Sci. 215:113–118. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng G, Huang R, Qiu G, Ge M, Wang J, Shu Q and Xu J: Mesenchymal stromal cell-derived extracellular vesicles: Regenerative and immunomodulatory effects and potential applications in sepsis. Cell Tissue Res. 374:1–15. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Weiss ARR and Dahlke MH: Immunomodulation by mesenchymal stem cells (MSCs): Mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol. 10:11912019. View Article : Google Scholar : PubMed/NCBI | |
|
Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wobus M, List C, Dittrich T, Dhawan A, Duryagina R, Arabanian LS, Kast K, Wimberger P, Stiehler M, Hofbauer LC, et al: Breast carcinoma cells modulate the chemoattractive activity of human bone marrow-derived mesenchymal stromal cells by interfering with CXCL12. Int J Cancer. 136:44–54. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kalimuthu S, Oh JM, Gangadaran P, Zhu L, Lee HW, Rajendran RL, Baek SH, Jeon YH, Jeong SY, Lee SW, et al: In vivo tracking of chemokine receptor CXCR4-engineered mesenchymal stem cell migration by optical molecular imaging. Stem Cells Int. 2017:80856372017. View Article : Google Scholar : PubMed/NCBI | |
|
Ratajczak MZ, Bujko K, Mack A, Kucia M and Ratajczak J: Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms. Leukemia. 32:2519–2526. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, Itoh J, Umezawa A, Kijima H, Fukuda S and Saijo Y: Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med. 17:579–587. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lu L, Chen G, Yang J, Ma Z, Yang Y, Hu Y, Lu Y, Cao Z, Wang Y and Wang X: Bone marrow mesenchymal stem cells suppress growth and promote the apoptosis of glioma U251 cells through downregulation of the PI3K/AKT signaling pathway. Biomed Pharmacother. 112:1086252019. View Article : Google Scholar : PubMed/NCBI | |
|
Bajetto A, Pattarozzi A, Corsaro A, Barbieri F, Daga A, Bosio A, Gatti M, Pisaturo V, Sirito R and Florio T: Different effects of human umbilical cord mesenchymal stem cells on glioblastoma stem cells by direct cell interaction or via released soluble factors. Front Cell Neurosci. 11:3122017. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng H, Zou W, Shen J, Xu L, Wang S, Fu YX and Fan W: Opposite effects of coinjection and distant injection of mesenchymal stem cells on breast tumor cell growth. Stem Cells Transl Med. 5:1216–1228. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Akimoto K, Kimura K, Nagano M, Takano S, To'a Salazar G, Yamashita T and Ohneda O: Umbilical cord blood-derived mesenchymal stem cells inhibit, but adipose tissue-derived mesenchymal stem cells promote, glioblastoma multiforme proliferation. Stem Cells Dev. 22:1370–1386. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Barcellos-de-Souza P, Comito G, Pons-Segura C, Taddei ML, Gori V, Becherucci V, Bambi F, Margheri F, Laurenzana A, Del Rosso M and Chiarugi P: Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-β1. Stem Cells. 34:2536–2547. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hill BS, Pelagalli A, Passaro N and Zannetti A: Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype. Oncotarget. 8:73296–73311. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tan HX, Xiao ZG, Huang T, Fang ZX, Liu Y and Huang ZC: CXCR4/TGF-β1 mediated self-differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and promoted colorectal carcinoma development. Cancer Biol Ther. 21:248–257. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Walter M, Liang S, Ghosh S, Hornsby PJ and Li R: Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene. 28:2745–2755. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai KS, Yang SH, Lei YP, Tsai CC, Chen HW, Hsu CY, Chen LL, Wang HW, Miller SA, Chiou SH, et al: Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology. 141:1046–1056. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang T, Lee YW, Rui YF, Cheng TY, Jiang XH and Li G: Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther. 4:702013. View Article : Google Scholar : PubMed/NCBI | |
|
El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, Csizmadia E, Mariani O, Zhu C, Campagne A, et al: Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci USA. 109:17460–17465. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M and Rameshwar P: Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-beta. J Immunol. 184:5885–5894. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gazdic M, Markovic BS, Jovicic N, Misirkic-Marjanovic M, Djonov V, Jakovljevic V, Arsenijevic N, Lukic ML and Volarevic V: Mesenchymal stem cells promote metastasis of lung cancer cells by downregulating systemic antitumor immune response. Stem Cells Int. 2017:62947172017. View Article : Google Scholar : PubMed/NCBI | |
|
Ramasamy R, Lam EWF, Soeiro I, Tisato V, Bonnet D and Dazzi F: Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth. Leukemia. 21:304–310. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
He N, Kong Y, Lei X, Liu Y, Wang J, Xu C, Wang Y, Du L, Ji K, Wang Q, et al: MSCs inhibit tumor progression and enhance radiosensitivity of breast cancer cells by down-regulating Stat3 signaling pathway. Cell Death Dis. 9:10262018. View Article : Google Scholar : PubMed/NCBI | |
|
Yulyana Y, Ho IAW, Sia KC, Newman JP, Toh XY, Endaya BB, Chan JKY, Gnecchi M, Huynh H, Chung AY, et al: Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling. Mol Ther. 23:746–756. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen HL, Li JJ, Jiang F, Shi WJ and Chang GY: MicroRNA-4461 derived from bone marrow mesenchymal stem cell exosomes inhibits tumorigenesis by downregulating COPB2 expression in colorectal cancer. Biosci Biotechnol Biochem. 84:338–346. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ho IAW, Toh HC, Ng WH, Teo YL, Guo CM, Hui KM and Lam PYP: Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells. 31:146–155. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Khalil C, Moussa M, Azar A, Tawk J, Habbouche J, Salameh R, Ibrahim A and Alaaeddine N: Anti-proliferative effects of mesenchymal stem cells (MSCs) derived from multiple sources on ovarian cancer cell lines: An in-vitro experimental study. J Ovarian Res. 12:702019. View Article : Google Scholar : PubMed/NCBI | |
|
DiDonato JA, Mercurio F and Karin M: NF-κB and the link between inflammation and cancer. Immunol Rev. 246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Kouzmina E, McCusker M, Rodin D, Boutros PC, Paige CJ and Rodin G: Pro- and anti-inflammatory cytokine associations with major depression in cancer patients. Psychooncology. 26:2149–2156. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ahechu P, Zozaya G, Martí P, Hernández-Lizoáin JL, Baixauli J, Unamuno X, Frühbeck G and Catalán V: NLRP3 inflammasome: A possible link between obesity-associated low-grade chronic inflammation and colorectal cancer development. Front Immunol. 9:29182018. View Article : Google Scholar : PubMed/NCBI | |
|
Mocellin S, Panelli MC, Wang E, Nagorsen D and Marincola FM: The dual role of IL-10. Trends Immunol. 24:36–43. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Núñez G and Zou W: Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res. 72:420–429. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT, Morrone G, Culig Z, Maitland NJ and Erb HHH: The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. Oncogenesis. 6:e3422017. View Article : Google Scholar : PubMed/NCBI | |
|
Setrerrahmane S and Xu H: Tumor-related iCnterleukins: Old validated targets for new anti-cancer drug development. Mol Cancer. 16:1532017. View Article : Google Scholar : PubMed/NCBI | |
|
Saeedi P, Halabian R and Fooladi AA: A revealing review of mesenchymal stem cells therapy, clinical perspectives and modification strategies. Stem Cell Investig. 6:342019. View Article : Google Scholar : PubMed/NCBI | |
|
Bortolotti F, Ukovich L, Razban V, Martinelli V, Ruozi G, Pelos B, Dore F, Giacca M and Zacchigna S: In vivo therapeutic potential of mesenchymal stromal cells depends on the source and the isolation procedure. Stem Cell Rep. 4:332–339. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fathi E, Sanaat Z and Farahzadi R: Mesenchymal stem cells in acute myeloid leukemia: A focus on mechanisms involved and therapeutic concepts. Blood Res. 54:165–174. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, He Y, Wang X, Lu F and Gao J: Adipose-derived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells. Oncol Rep. 41:2126–2136. 2019.PubMed/NCBI | |
|
Dührsen L, Hartfuß S, Hirsch D, Geiger S, Maire CL, Sedlacik J, Guenther C, Westphal M, Lamszus K, Hermann FG and Schmidt NO: Preclinical analysis of human mesenchymal stem cells: Tumor tropism and therapeutic efficiency of local HSV-TK suicide gene therapy in glioblastoma. Oncotarget. 10:6049–6061. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dissanayake S, Denny WA, Gamage S and Sarojini V: Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. J Control Release. 250:62–76. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lagoa R, Silva J, Rodrigues JR and Bishayee A: Advances in phytochemical delivery systems for improved anticancer activity. Biotechnol Adv. 38:1073822020. View Article : Google Scholar : PubMed/NCBI | |
|
Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI | |
|
Ahn JO, Lee HW, Seo KW, Kang SK, Ra JC and Youn HY: Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma. PLoS One. 8:e748972013. View Article : Google Scholar : PubMed/NCBI | |
|
Shen CJ, Chan TF, Chen CC, Hsu YC, Long CY and Lai CS: Human umbilical cord matrix-derived stem cells expressing interferon-β gene inhibit breast cancer cells via apoptosis. Oncotarget. 7:34172–34179. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan ZQ, Kolluri KK, Sage EK, Gowers KHC and Janes SM: Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy. Cytotherapy. 17:885–896. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Marini I, Siegemund M, Hutt M, Kontermann RE and Pfizenmaier K: Antitumor activity of a mesenchymal stem cell line stably secreting a tumor-targeted TNF-related apoptosis-inducing ligand fusion protein. Front Immunol. 8:5362017. View Article : Google Scholar : PubMed/NCBI | |
|
Guiho R, Biteau K, Grisendi G, Chatelais M, Brion R, Taurelle J, Renault S, Heymann D, Dominici M and Redini F: In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models. Cytotherapy. 20:1037–1045. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Shamili FH, Bayegi HR, Salmasi Z, Sadri K, Mahmoudi M, Kalantari M, Ramezani M and Abnous K: Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model. Int J Pharm. 549:218–229. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Du J, Xu X, Xu C and Song W: IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway. J Immunol Res. 2014:e3180982014. View Article : Google Scholar | |
|
You Q, Yao Y, Zhang Y, Fu S, Du M and Zhang G: Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo. Mol Med Rep. 12:4859–4866. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao W, Cheng J, Shi P and Huang J: Human umbilical cord mesenchymal stem cells with adenovirus-mediated interleukin 12 gene transduction inhibits the growth of ovarian carcinoma cells both in vitro and in vivo. Nan Fang Yi Ke Da Xue Xue Bao. 31:903–907. 2011.(In Chinese). PubMed/NCBI | |
|
Zhang X, Zhang L, Xu W, Qian H, Ye S, Zhu W, Cao H, Yan Y, Li W, Wang M, et al: Experimental therapy for lung cancer: Umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr Cancer Drug Targets. 13:92–102. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nowakowski A, Walczak P, Lukomska B and Janowski M: Genetic engineering of mesenchymal stem cells to induce their migration and survival. Stem Cells Int. 2016:e49560632016. View Article : Google Scholar : PubMed/NCBI | |
|
Wei W, Huang Y, Li D, Gou HF and Wang W: Improved therapeutic potential of MSCs by genetic modification. Gene Ther. 25:538–547. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ocansey DKW, Pei B, Yan Y, Qian H, Zhang X, Xu W and Mao F: Improved therapeutics of modified mesenchymal stem cells: An update. J Transl Med. 18:422020. View Article : Google Scholar : PubMed/NCBI | |
|
Phillips MI and Tang YL: Genetic modification of stem cells for transplantation. Adv Drug Deliv Rev. 60:160–172. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bobis-Wozowicz S, Miekus K, Wybieralska E, Jarocha D, Zawisz A, Madeja Z and Majka M: Genetically modified adipose tissue-derived mesenchymal stem cells overexpressing CXCR4 display increased motility, invasiveness, and homing to bone marrow of NOD/SCID mice. Exp Hematol. 39:686–696. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pelagalli A, Nardelli A, Lucarelli E, Zannetti A and Brunetti A: Autocrine signals increase ovine mesenchymal stem cells migration through Aquaporin-1 and CXCR4 overexpression. J Cell Physiol. 233:6241–6249. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Song SW, Chang W, Song BW, Song H, Lim S, Kim HJ, Cha MJ, Choi E, Im SH, Chang BC, et al: Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium. Stem Cells. 27:1358–1365. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fan YX, Gu CH, Zhang YL, Zhong BS, Wang LZ, Zhou ZR, Wang ZY, Jia RX and Wang F: Oct4 and Sox2 overexpression improves the proliferation and differentiation of bone mesenchymal stem cells in Xiaomeishan porcine. Genet Mol Res. 12:6067–6079. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Han SM, Han SH, Coh YR, Jang G, Ra JC, Kang SK, Lee HW and Youn HY: Enhanced proliferation and differentiation of Oct4- and Sox2-overexpressing human adipose tissue mesenchymal stem cells. Exp Mol Med. 46:e1012014. View Article : Google Scholar : PubMed/NCBI | |
|
Becker AD and Riet IV: Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? World J Stem Cells. 8:73–87. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
DelaRosa O, Dalemans W and Lombardo E: Toll-like receptors as modulators of mesenchymal stem cells. Front Immunol. 3:1822012. View Article : Google Scholar : PubMed/NCBI | |
|
Najar M, Krayem M, Meuleman N, Bron D and Lagneaux L: Mesenchymal stromal cells and toll-like receptor priming: A critical review. Immune Netw. 17:89–102. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mekhemar MK, Dörfer CE and El-Sayed KMF: Toll-like receptors: The key of immunotherapy in MSCs. Immunoregulatory aspects of immunotherapy. IntechOpen; pp. 1732018 | |
|
Waterman RS, Tomchuck SL, Henkle SL and Betancourt AM: A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One. 5:e100882010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J and Hematti P: Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp Hematol. 37:1445–1453. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cassatella MA, Mosna F, Micheletti A, Lisi V, Tamassia N, Cont C, Calzetti F, Pelletier M, Pizzolo G and Krampera M: Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells. 29:1001–1011. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hall SRR, Tsoyi K, Ith B, Padera RF Jr, Lederer JA, Wang Z, Liu X and Perrella MA: Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: The importance of neutrophils. Stem Cells. 31:397–407. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang W and Xu J: Immune modulation by mesenchymal stem cells. Cell Prolif. 53:e127122019.PubMed/NCBI | |
|
Kudlik G, Hegyi B, Czibula Á, Monostori É, Buday L and Uher F: Mesenchymal stem cells promote macrophage polarization toward M2b-like cells. Exp Cell Res. 348:36–45. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC and Moretta L: Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 111:1327–1333. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gonzalez H, Hagerling C and Werb Z: Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. 32:1267–1284. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, et al: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35 (Suppl):S185–S198. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D and Shah K: Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci USA. 114:E6157–E6165. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Y, Zhang Z, Xu X, Xu Z, Wang S, Huang D, Li Y, Mou X, Liu F and Xiang C: Menstrual blood-derived stem cells as delivery vehicles for oncolytic adenovirus virotherapy for colorectal cancer. Stem Cells Dev. 28:882–896. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mahasa KJ, Pillis Ld, Ouifki R, Eladdadi A, Maini P, Yoon AR and Yun CO: Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy. Sci Rep. 10:4252020. View Article : Google Scholar : PubMed/NCBI | |
|
Pessina A, Coccè V, Pascucci L, Bonomi A, Cavicchini L, Sisto F, Ferrari M, Ciusani E, Crovace A, Falchetti ML, et al: Mesenchymal stromal cells primed with paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice. Br J Haematol. 160:766–778. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gilazieva Z, Tazetdinova L, Arkhipova S, Solovyeva V and Rizvanov A: Effect of cisplatin on ultrastructure and viability of adipose-derived mesenchymal stem cells. BioNanoScience. 6:534–539. 2016. View Article : Google Scholar | |
|
Nicolay NH, Perez RL, Rühle A, Trinh T, Sisombath S, Weber KJ, Ho AD, Debus J, Saffrich R and Huber PE: Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin. Sci Rep. 6:200352016. View Article : Google Scholar : PubMed/NCBI | |
|
Pascucci L, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Viganò L, Locatelli A, Sisto F, Doglia SM, et al: Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. J Control Release. 192:262–270. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pessina A, Bonomi A, Coccè V, Invernici G, Navone S, Cavicchini L, Sisto F, Ferrari M, Viganò L, Locatelli A, et al: Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One. 6:e283212011. View Article : Google Scholar : PubMed/NCBI | |
|
Bonomi A, Coccè V, Cavicchini L, Sisto F, Dossena M, Balzarini P, Portolani N, Ciusani E, Parati E, Alessandri G and Pessina A: Adipose tissue-derived stromal cells primed in vitro with paclitaxel acquire anti-tumor activity. Int J Immunopathol Pharmacol. 26 (Suppl 1):S33–S41. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Coccè V, Franzè S, Brini AT, Giannì AB, Pascucci L, Ciusani E, Alessandri G, Farronato G, Cavicchini L, Sordi V, et al: In vitro anticancer activity of extracellular vesicles (EVs) secreted by gingival mesenchymal stromal cells primed with paclitaxel. Pharmaceutics. 11:612019. View Article : Google Scholar : PubMed/NCBI | |
|
Coccè V, Farronato D, Brini AT, Masia C, Giannì AB, Piovani G, Sisto F, Alessandri G, Angiero F and Pessina A: Drug loaded gingival mesenchymal stromal cells (GinPa-MSCs) inhibit in vitro proliferation of oral squamous cell carcinoma. Sci Rep. 7:93762017. View Article : Google Scholar : PubMed/NCBI | |
|
Layek B, Sadhukha T, Panyam J and Prabha S: Nano-engineered mesenchymal stem cells increase therapeutic efficacy of anticancer drug through true active tumor targeting. Mol Cancer Ther. 17:1196–1206. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Moku G, Layek B, Trautman L, Putnam S, Panyam J and Prabha S: Improving payload capacity and anti-tumor efficacy of mesenchymal stem cells using TAT peptide functionalized polymeric nanoparticles. Cancers (Basel). 11:4912019. View Article : Google Scholar : PubMed/NCBI | |
|
Altun İ and Sonkaya A: The most common side effects experienced by patients were receiving first cycle of chemotherapy. Iran J Public Health. 47:1218–1219. 2018.PubMed/NCBI | |
|
Kim W, Lee SK, Kwon YW, Chung SG and Kim S: Pioglitazone-primed mesenchymal stem cells stimulate cell proliferation, collagen synthesis and matrix gene expression in tenocytes. Int J Mol Sci. 20:4722019. View Article : Google Scholar : PubMed/NCBI | |
|
Hong Y, Kim YS, Hong SH and Oh YM: Therapeutic effects of adipose-derived stem cells pretreated with pioglitazone in an emphysema mouse model. Exp Mol Med. 48:e2662016. View Article : Google Scholar : PubMed/NCBI | |
|
Park JS, Kim HK, Kang EY, Cho R and Oh YM: Potential therapeutic strategy in chronic obstructive pulmonary disease using pioglitazone-augmented Wharton's jelly-derived mesenchymal stem cells. Tuberc Respir Dis (Seoul). 82:158–165. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Khoo BY, Nadarajan K, Shim SY, Miswan N, Zang CB, Possinger K and Elstner E: Pretreatment of BMSCs with TZD solution decreases the proliferation rate of MCF-7 cells by reducing FGF4 protein expression. Mol Med Rep. 13:3406–3414. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tsubaki M, Takeda T, Tomonari Y, Kawashima K, Itoh T, Imano M, Satou T and Nishida S: Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPARγ-independent pathway. J Cell Physiol. 233:3638–3647. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Moghareabed R, Hemati S, Akhavan A, Emami H, Farghadani M, Roayaei M, Tavajoh S and Feizi A: Randomized phase II clinical trial of pioglitazone plus chemotherapy versus chemotherapy alone in patients with metastatic breast cancer. J Glob Oncol. 5:832019. View Article : Google Scholar | |
|
Esmaeili S, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Salari S, Gharehbaghian A, Hamidpour M and Bashash D: Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone. Int J Biochem Cell Biol. 122:1057392020. View Article : Google Scholar : PubMed/NCBI | |
|
Shinmura D, Togashi I, Miyoshi S, Nishiyama N, Hida N, Tsuji H, Tsuruta H, Segawa K, Tsukada Y, Ogawa S and Umezawa A: Pretreatment of human mesenchymal stem cells with pioglitazone improved efficiency of cardiomyogenic transdifferentiation and cardiac function. Stem Cells. 29:357–366. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Cai J, Huang F, Zhu M, Zhang Q, Yang T, Zhang X, Qian H and Xu W: Pre-treatment of human umbilical cord-derived mesenchymal stem cells with interleukin-6 abolishes their growth-promoting effect on gastric cancer cells. Int J Mol Med. 35:367–375. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
von Bahr L, Sundberg B, Lönnies L, Sander B, Karbach H, Hägglund H, Ljungman P, Gustafsson B, Karlsson H, Blanc KL and Ringdén O: Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant. 18:557–564. 2012. View Article : Google Scholar : PubMed/NCBI |
